Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study

Blood (2024) 144 (Supplement 1): 1869.

https://doi.org/10.1182/blood-2024-200936

Published: 2024

Journal Articles

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Michael Wang, Wojciech Jurczak, Marek Trněný, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary-Margaret Keating, Tom van Meerten, Ruben Fernandez Alvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade, Marc Andre, Marc Hoffmann, Edith Szafer Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam

Blood (2023) 142 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2023-191921

Published: 2023

Journal Articles

Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study

Constantine S. Tam, MD, Radhakrishnan Ramchandren, MD, Robert Chen, MD, Lionel Karlin, MD, Geoffrey Chong, MD, Wojciech Jurczak, MD PhD, Ka Lung Wu, MD PhD, Mark Bishton, MBChB, MRCP, FRCPath, PhD, Graham P. Collins, MD DPhil, Paul Eliadis, MBBS, FRACP, FRCPA, Frédéric Peyrade, MD, Edith Szafer-Glusman, PhD, Yihua Lee, PhD, Karl Eckert, BA, Jutta K. Neuenburg, MD PhD, Michael Wang, MD

Blood (2020) 136 (Supplement 1): 39–41.

https://doi.org/10.1182/blood-2020-134392

Published: 2020

Journal Articles

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2019) 134 (Supplement_1): 761.

https://doi.org/10.1182/blood-2019-121521

Published: 2019

Journal Articles

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL

Andre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, Javier Munoz, David S. Morgan, Nam H. Dang, Mark Knapp, Maria Delioukina, Edwin Kingsley, Jerry Ping, Darrin M. Beaupre, Jutta K. Neuenburg, Jia Ruan

Blood (2019) 134 (13): 1024–1036.

https://doi.org/10.1182/blood.2018891598

Published: 2019

Includes: Supplemental data

Journal Articles

The iR 2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 402.

https://doi.org/10.1182/blood-2018-99-111163

Published: 2018

Journal Articles

Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study

Nathan Fowler, MD, Loretta Nastoupil, MD, Sven de Vos, MD PhD, Mark Knapp, MD, Ian W. Flinn, MD PhD, Robert W Chen, MD, Ranjana H Advani, MD, Sumeet Bhatia, MD, Peter Martin, MD, Raul Mena, MD, Samuel Suzuki, MS, MBA, Darrin M. Beaupre, MD PhD, Jutta K. Neuenburg, MD PhD, M. Lia Palomba, MD

Blood (2016) 128 (22): 1804.

https://doi.org/10.1182/blood.V128.22.1804.1804

Published: 2016

Journal Articles

A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Andre Goy, MD, Radhakrishnan Ramchandren, MD, Nilanjan Ghosh, MD PhD, Javier Munoz, MD, David S. Morgan, MD, Nam H. Dang, MD PhD, Mark Knapp, MD, Maria Delioukina, MD, Edwin C. Kingsley, MD, Anh Tran, BS, Jerry Ping, PhD, Darrin M. Beaupre, MD PhD, Jutta K. Neuenburg, MD PhD, Jia Ruan, MD PhD

Blood (2016) 128 (22): 473.

https://doi.org/10.1182/blood.V128.22.473.473

Published: 2016

Journal Articles

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

Patrick P. Ng, Daniel K. Lu, Juthamas Sukbuntherng, Jutta K. Neuenburg, Danelle F. James, Betty Y. Chang, PhD

Blood (2015) 126 (23): 3998.

https://doi.org/10.1182/blood.V126.23.3998.3998

Published: 2015

Journal Articles

Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study

Nathan Fowler, MD, Loretta Nastoupil, MD, Sven de Vos, MD PhD, Mark Knapp, MD, Ian W. Flinn, MD PhD, Robert Chen, Ranjana H Advani, MD, Sumeet Bhatia, MD, Peter Martin, MD, Raul Mena, MD, Samuel Suzuki, MS, MBA, Darrin M. Beaupre, MD, Jutta K. Neuenburg, MD, M. Lia Palomba, MD

Blood (2015) 126 (23): 470.

https://doi.org/10.1182/blood.V126.23.470.470

Published: 2015

Journal Articles

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

Blood (2015) 126 (7): 842–850.

https://doi.org/10.1182/blood-2014-12-617522

Published: 2015

Includes: Supplemental data

NARROW

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL

The iR 2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma

Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1 + Arm 2 Results from a Multicenter, Open-Label Phase 2 Study

A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only